Comparative Study of Rivaroxaban and Warfarin for Treating the Patients With Left Ventricular Thrombus
10.3969/j.issn.1000-3614.2015.06.012
- VernacularTitle:利伐沙班与华法林治疗左心室心尖部血栓的疗效比较
- Author:
Xiufen LI
;
Zhenrong GE
- Publication Type:Journal Article
- Keywords:
Rivaroxaban;
Warfarin;
Left ventricular thrombus;
Anticoagulant drug
- From:
Chinese Circulation Journal
2015;(6):559-561
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the safety and efifcacy of rivaroxaban and warfarin for treating the patients with left ventricular thrombus. Methods: A total of 31 patients with left ventricular thrombus were studied, the patients were randomly divided into 2 groups:Warfarin group, n=16, the patients initially received oral warfarin and low molecular weight heparin at (2.5-3) mg/day, when the INR value reached 2.0-3.0, heparin was stopped and warfarin was continued, the INR value was monitored every 3 days for 3 times, when INR value was stably kept at 2.0-3.0, it was then monitored for every 2 weeks. Rivaroxaban group,n=15, the patients received oral rivaroxaban at 10 mg twice a day. All patients were followed-up for 3 months, the thrombus remission time, new onset of thrombosis, embolism and bleeding events during treatment period were compared between 2 groups. Results: The patients’ age, gender, complication, size of thrombus and medication were similar between 2 groups. Compared with Warfarin group, Rivaroxaban group had the shorter thrombus remission time, (60.00±5.50)d vs (71.00±8.50) d,P<0.01, while the new onset of thrombosis and embolism events as cerebral embolism and systemic embolism were similar between 2 groups, Warfarin group had slightly higher bleeding events, allP>0.05. Conclusion: Rivaroxaban had better effect than warfarin for treating the patients with left ventricular thrombus without increasing the risk of bleeding.
